share_log

VITASOY INTERNATIONAL(00345.HK):1HFY24 RESULTS WERE IN-LINE; EXPECTING 2HFY24 SALES TO RESTORE POSITIVE YOY GROWTH WITH IMPROVING PROFITABILITY

VITASOY INTERNATIONAL(00345.HK):1HFY24 RESULTS WERE IN-LINE; EXPECTING 2HFY24 SALES TO RESTORE POSITIVE YOY GROWTH WITH IMPROVING PROFITABILITY

維他奶國際 (00345.HK): 1HFY24 業績符合預期;預計24財年下半年的銷售額將恢復正增長,盈利能力提高
国泰君安国际 ·  2023/11/22 15:56

Maintain "Accumulate" rating on Vitasoy International (Vitasoy, or the "Company") with a TP at HK$13.20. We keep our earnings forecasts for FY24-FY26 unchanged at HK$0.149/ HK$0.263/ HK$0.377 in terms of EPS. For Vitasoy, although challenges remain ahead due to weak consumption sentiment, intensified market competition and lasting cost pressure, the management has shown more confidence in the Company's long-term perspective. Three fundamental pillars are innovation, execution and expansion. Currently, the pessimism has been priced in to a certain extent. In the short run, the management reiterated that Vitasoy would 1) deliver positive yoy top-line growth in 2HFY24; and 2) increase structural profitability in FY24. Our TP of HK$13.20 is based on 35x FY26F PER.

維持維他奶國際(維他奶或 “公司”)的 “累積” 評級,目標價爲13.20港元。就每股收益而言,我們對 FY24-FY26 的收益預期維持不變,爲0.149港元/0.263港元/0.377港元。對於Vitasoy而言,儘管由於消費情緒疲軟、市場競爭加劇和持續的成本壓力,挑戰仍然存在,但管理層對公司的長期前景表現出了更大的信心。三個基本支柱是創新、執行和擴張。目前,悲觀情緒已在一定程度上被考慮在內。在短期內,管理層重申,維他奶將 1) 在 2HFY24 中實現收入同比正增長;2) 在 24 財年提高結構性盈利能力。我們的目標價爲13.20港元,基於 FY26F 市盈率的35倍。

1HFY24 results in-line: In 1HFY24, Vitasoy's mainland China sales declined 11% yoy (or 6% yoy in terms of RMB) to HK$1,962 mn mainly due to high comparable base in 2QFY23. Hong Kong sales rose 4% yoy to HK$1,121 mn driven by strong momentum from on-the-go consumption behind both core and innovative products. Overall gross margin was up 2.8 ppts yoy to 50.5% as a result of price hikes and continuous cost control measures, beating market expectations. As a whole, shareholders' profit grew 15% yoy (or 99% yoy if excluding currency impact and COVID-19 related government subsidies) to HK$163 mn, basically in line with our previous expectation.

1HFY24 業績符合預期:在 1HFY24 中,維他奶在中國大陸的銷售額同比下降11%(按人民幣計算同比下降6%),至19.62億港元,這主要是由於2QFY23 的可比基數很高。香港銷售額同比增長4%,達到11.21億港元,這得益於核心和創新產品背後的強勁消費勢頭。由於價格上漲和持續的成本控制措施,整體毛利率同比增長2.8個百分點至50.5%,超出市場預期。總體而言,股東的利潤同比增長15%(如果不包括貨幣影響和 COVID-19 相關的政府補貼,則同比增長99%),達到1.63億港元,基本符合我們之前的預期。

Expecting mainland China business to maintain profitable growth momentum in FY24. The management aims to restore positive yoy sales growth in 2HFY24. Amid macro headwinds, Vitasoy should continue to focus on aggressively consolidating market share in the mainland China market. Three aspects could be monitored. (1) Product innovation.

預計中國大陸業務將在24財年保持盈利增長勢頭。管理層的目標是在 2HFY24 中恢復同比正的銷售增長。在宏觀不利因素下,Vitasoy應繼續專注於積極鞏固在中國大陸市場的市場份額。可以監控三個方面。(1)產品創新。

Since the market is more likely to stay competitive with more active investments and new entrants, the Company needs to drive its core portfolio by actively introducing new products. (2) Execution. The senior management reiterated the importance of brand building/ A&P events for offline distribution channels. For internal management structure, we are looking forward to seeing more changes since Ms. May Lo has been appointed as the Deputy Chairman of the Board with effect from 21 November 2023. (3) Expansion. In addition to its principal markets (such as south/ central/ east China), the Company may restart offline expansion in its emerging markets (such as north/ west China). Meanwhile, we think that the Company should further expand online sales on the basis of a more stabilized pricing system.

由於市場更有可能通過更活躍的投資和新進入者來保持競爭力,因此公司需要通過積極推出新產品來推動其核心投資組合。(2)執行。高級管理層重申了品牌建設/A&P活動對線下分銷渠道的重要性。在內部管理結構方面,自從羅美美女士被任命爲董事會副主席以來,我們期待看到更多變化,自2023年11月21日起生效。(3) 擴張。除主要市場(例如華南/華中/華東)外,公司可能在其新興市場(例如華北/華西)重啓線下擴張。同時,我們認爲公司應在更穩定的定價體系基礎上進一步擴大在線銷售。

Expecting operating margin to gradually rise. Positives include economies of scale with lower D&A expenditure, price hikes, and declining packaging material prices and logistics costs, while negatives include high sugar price and potential S&D expense increases. Apart from ongoing cost optimization initiatives, the management will evaluate the ROI of A&P activities more carefully. We forecast Vitasoy's operating margin to rise 2.4 ppts/ 1.8 ppts/ 1.7 ppts YoY to 4.0%/ 5.8%/ 7.5% in FY24-FY26 respectively, still lower than the FY19-FY21 average of 11.3%.

預計營業利潤率將逐漸上升。積極因素包括規模經濟,併購支出降低,價格上漲,包裝材料價格和物流成本下降,而負面因素包括糖價居高不下和S&D支出可能增加。除了持續的成本優化計劃外,管理層還將更仔細地評估A&P活動的投資回報率。我們預計,在 FY24-FY26 中,維塔索伊的營業利潤率將同比增長2.4個百分點/1.8個百分點/1.7個百分點至4.0%/5.8%/7.5%,仍低於 FY19-FY21 11.3%的平均水平。

Risks: Weaker-than-expected retail sales sentiment in Vitasoy's operating regions; slower-than-expected expansion in mainland China business segment; intensified competition.

風險:維他奶運營區域的零售銷售情緒低於預期;中國大陸業務板塊的擴張低於預期;競爭加劇。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論